Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: chemoradiotherapy Comparison: radiotherapy Outcome: neurocognitive impairment at 3 years after treatment · people with glioma surviving at least two years
The intervention showed no clear difference in intervention: chemoradiotherapy Comparison: radiotherapy Outcome:… (low certainty).
1 finding from 1 review
Intervention not reported
Intervention: stereotactic conformal radiotherapy Comparison: radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
The intervention showed no clear difference in intervention: stereotactic conformal radiotherapy Comparison:… (low certainty).
1 finding from 1 review
Interruptions to cancer treatment (radiotherapy interruptions) · Adults with cancer receiving treatment
Granulocyte-colony stimulating factor (G-CSF) showed no clear difference in interruptions to cancer treatment (radiotherapy interruptions) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (unscheduled radiotherapy breaks of 5 or more days) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (unscheduled radiotherapy breaks… compared with placebo; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (radiotherapy breaks longer than two days) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in interruptions to cancer treatment (radiotherapy breaks longer than… compared with placebo; GRADE not reported.
1 finding from 1 review
Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (time‐to‐event outcome): chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
2 findings from 1 review
Long‐term mortality (time‐to‐event outcome): radiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event outcome): radiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).
1 finding from 1 review
Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (binary): definitive chemoradiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
1 finding from 1 review
Radiotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to lower radiotherapy compliance compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy compared with primary surgery (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
It is very uncertain whether the intervention changes all‐cause mortality at 31 to 100 days (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Number of participants with any bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in number of participants with any bleeding (0 to 3 months) (low certainty).
1 finding from 1 review